+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study



Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study



Bulletin of the World Health Organization 70(2): 233-239



The immunogenicity of 4 different dosages of yeast-derived hepatitis B vaccine (Merck, Sharp and Dohme: 0.6 mcg, 1.25 mcg, and 5.0 mcg), administered at 0, 1, and 6 months (0-1-6 schedule) intramuscularly, was evaluated in 122 seronegative healthy children ages 1-12. 3 months after the 1st dose, 83.9-100% of the vaccinees seroconverted. Peak geometric mean titers (GMT) of between 1088 mIU/ml and 1699 mIU/ml were attained 3 months after completion of the vaccination schedule. After 24 months, anti-HBs (antibody to hepatitis B surface antigen) was detected in 93.1-100% of the vaccines, but the GMT dropped to between 214.3 mIU/ml and 303.5 mIU/ml. After 48 months, 88.8-100% of the vaccinees continued to possess anti-HBs and 70.3-87% had titers above 10 mIU/ml. As expected, the GMT declined further to between 72.6 mIU/ml and 118.8 mIU/ml. There were no significant differences in seroconversion rates and GMT among the different dosage groups. All the vaccinees remained asymptomatic and free from hepatitis B virus infection. The study demonstrated that reduced dosages of the vaccine (0.6 mcg, 1.25 mcg, and 2.5 mcg) were as immunogenic as the standard dose (5 mcg); the 2.5 mcg dose was recommended for the national childhood immunization program in Singapore. No booster is needed for at least 4 years postvaccination. (author's)

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039635746

Download citation: RISBibTeXText

PMID: 1600584


Related references

Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses. Hepatology 18(4): 763-767, 1993

Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 29(3): 924-927, 1999

The immune response of low dose recombinant DNA hepatitis B vaccine in teenagers in Singapore. Transactions of the Royal Society of Tropical Medicine and Hygiene 84(5): 731-732, 1990

Comparison study of the immunogenicity and safety of 5- and 10-microgram dosages of a recombinant hepatitis B vaccine in healthy children. Pediatric Infectious Disease Journal 15(9): 768-771, 1996

Five-year follow-up of immune response after one or two doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. Journal of Viral Hepatitis 22(4): 453-458, 2015

Five-year follow-up of immune response to hepatitis B vaccine in juveniles. Chinese Medical Journal 106(2): 97-99, 1993

A five year follow up study of two different doses of recombinant hepatitis B vaccine in Egyptian children. Hepatology 28(4 Part 2): 726A, 1998

Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-Year follow-up study. Vaccine 19(28-29): 3936-3939, 16 July, 2001

Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine. Pediatric Hematology and Oncology 13(5): 425-431, 1996

Successful immune response to a recombinant hepatitis B vaccine in children after liver transplantation. Journal of Pediatric Gastroenterology and Nutrition 32(2): 168-170, 2001

Two different dosages of yeast derived recombinant hepatitis B vaccines: A comparison of immunogenicity. Vaccine 14(2): 135-137, 1996

Immunogenicity, reactogenicity and comparison of two doses of recombinant DNA yeast-derived hepatitis B vaccine in Ethiopian children. Tropical and Geographical Medicine 43(1-2): 220-227, 1991

Clinical evaluation of a yeast recombinant hepatitis B vaccine in healthy hospital staff in Singapore. Annals of the Academy of Medicine Singapore 17(2): 185-189, 1988

Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 257(19): 2612-2616, 1987

Comparison study of the immunogenicity of different types and dosages of recombinant hepatitis B vaccine in healthy neonates. Journal of Tropical Pediatrics 47(1): 60-62, 2001